JPM: Boehringer inks Enara deal to source 'dark antigens' for cancer immunotherapies

Boehringer Ingelheim has partnered with Enara Bio to discover novel shared antigens for its growing cancer vaccine and bispecific activities. The agreement positions Boehringer to access novel “dark antigens” discovered by Enara.